Overview

Comparison of Two Antibiotic Regimen (Meropenem Versus Meropenem+Moxifloxacin)in the Treatment of Severe Sepsis and Septic Shock

Status:
Completed

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

Summary

Severe sepsis and septic shock are diseases of infectious origin with a high risk of death. Antibiotic therapy is mandatory but it is unknown whether one antibiotic alone is sufficient for initial therapy. The purpose of this study is to compare a therapy with meropenem alone or the combination of meropenem plus moxifloxacin in the treatment of severe sepsis/ septic shock. Patients randomly receive one of the two treatments for at least 7 days but not longer than 14 days.

Phase:

Phase 3

Details

Lead Sponsor:

Kompetenznetz Sepsis

Collaborators:

AstraZeneca
Bayer

Treatments:

Anti-Bacterial Agents
Antibiotics, Antitubercular
Fluoroquinolones
Meropenem
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Thienamycins